About Arteriocyte
Arteriocyte is a company based in Hopkinton (United States) founded in 2007 by Donald Brown. Arteriocyte has raised $15.11 million across 6 funding rounds from investors including HHS, Cleveland Clinic Innovations and DW Management Services. Arteriocyte offers products and services including Magellan, Influx, and InQu. Arteriocyte operates in a competitive market with competitors including Hemotune, Medcura, ExThera Medical, Lindis Blood Care and CytoPherx, among others.
- Headquarter Hopkinton, United States
- Founders Donald Brown
- SectorsHealthcare
- Email••••••••
- Website arteriocyte.com
- Social LinkedIn X YouTube
- Total Equity Funding$15.11M (USD)
in 6 rounds
- Latest Funding Round$2.48M (USD), Grant
Mar 2011
- InvestorsHHS
& 3 more
Products & Services of Arteriocyte
Arteriocyte offers a comprehensive portfolio of products and services, including Magellan, Influx, and InQu.
System for creating platelet-rich plasma and bone marrow therapies.
Allograft products for bone grafting and healing applications.
Biosynthetic bone graft for faster fusion in medical procedures.
Apps and channels of Arteriocyte
its YouTube channel Isto Biologics has 215 subscribers and 23 videos.
Videos from Arteriocyte
The most watched videos on Arteriocyte's YouTube channel, Isto Biologics (215 subscribers). Click a video to play it here.
More on Isto Biologics.
Funding Insights of Arteriocyte
Arteriocyte has successfully raised a total of $15.11M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.48 million completed in March 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.11M
- Total Rounds 6
- Last Round Grant — $2.48M
- First Round $15.01M
(Nov 2007)
- Investors Count 3
All 6 funding rounds of Arteriocyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2011 | $2.48M | Grant | – | – | |
| Mar 2011 | $150,000 | Debt – Convertible | – | – | – |
| Jul 2009 | $100,000 | Series A | – | – | – |
| Sep 2008 | $2.48M | Grant | – | – | |
| Jan 2008 | $509,000 | Grant | – | – | |
| Nov 2007 | $15.01M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Arteriocyte
Arteriocyte has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Cleveland Clinic Innovations and DW Management Services.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health tech startups are supported through incubation services. | 2007 | gcic.org | Cleveland, United States | |
- | – | dwhp.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Arteriocyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arteriocyte
1 people are tracked at Arteriocyte (1 in leadership).
| Name | Role | Group |
|---|---|---|
Donald Brown | Founder | Leadership |
Complete people profiles for Arteriocyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Arteriocyte
3 dated milestones of Arteriocyte across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Arteriocyte is founded.
- Funding First funding round of $15.0M.
- Funding Latest funding round, Grant, of $2.5M.
Competitors of Arteriocyte
Arteriocyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemotune, Medcura, ExThera Medical, Lindis Blood Care and CytoPherx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hemotune.ch | 2017 | Zurich, Switzerland | $28.86M | – | Developer of a device for blood purification | |
| medcurainc.com | 2019 | United States | $87.35M | – | Developer of the device for controlling bleeding | |
| extheramedical.com | 2007 | Berkeley, United States | $54.59M | 23 | Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking | |
| lindis-bloodcare.com | 2006 | Hennigsdorf, Germany | $1.89M | – | Innovative solutions for safer blood transfusions are developed. | |
| cytopherx.com | 1994 | Ann Arbor, United States | $47.69M | – | Cytopheresis systems for inflammatory conditions | |
| artblood.kr | 2022 | Seoul, South Korea | $4.8M | – | Developer of a cell-based extracorporeal blood production system | |
| antrad.se | 2008 | Stockholm, Sweden | $3.5M | – | Thawed, ready to use blood plasma | |
| syngeninc.com | 2009 | Sacramento, United States | $16.81M | – | Develops cell separation tools and accessories | |
| veli.co | 1992 | Beverly, United States | – | 33 | Developer of blood and plasma products for transfusion |
Detailed competitors of Arteriocyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arteriocyte
Websites that share an audience with Arteriocyte (arteriocyte.com).
Websites whose visitors overlap most with Arteriocyte. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| plcmed.com | 28% | – | – | View details |
Latest news on Arteriocyte
Complete news archive for Arteriocyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Arteriocyte
10 companies that operate in the same segment as Arteriocyte (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Arteriocyte
Arteriocyte was founded in 2007.
Arteriocyte is headquartered in Hopkinton, United States. It is registered at Hopkinton, Massachusetts, United States.
Arteriocyte is a funded company, having raised a total of $15.11M across 6 funding rounds to date. The company's 1st funding round was a Series A of $15.01M, raised on Nov 2007.
Arteriocyte Medical Systems, is a medical device company that develops products to accelerate healing in patients. Its lead product, Magellan Autologous Platelet Separator provides surgeons the ability to fractionate peripheral blood, or a mixture of blood and aspirated bone marrow from a patient. It also produces Demineralized Bone Matrix in the form of powder - MAR0Match or in the form of gel - MAR0Fuse. Other products include Magellan PRP to prepare Platelet Rich Plasma, and MAR0Max kit that provides the surgeon tools needed to Aspirate, Concentrate and Deliver a mixture of whole blood and bone marrow.
Arteriocyte's top competitors include Medcura, ExThera Medical and Lindis Blood Care.
Arteriocyte offers Magellan, Influx, and InQu.
Arteriocyte has 3 investors. Key investors include HHS, Cleveland Clinic Innovations, and DW Management Services.